Free Trial

740 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Prospera Financial Services Inc

Regeneron Pharmaceuticals logo with Medical background

Prospera Financial Services Inc bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 740 shares of the biopharmaceutical company's stock, valued at approximately $778,000.

Several other hedge funds have also made changes to their positions in REGN. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 10 shares during the period. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $33,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $6.50 during trading on Friday, reaching $738.00. 1,029,511 shares of the stock were exchanged, compared to its average volume of 873,589. The stock has a 50 day simple moving average of $945.07 and a 200-day simple moving average of $1,026.63. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $81.10 billion, a P/E ratio of 18.26, a price-to-earnings-growth ratio of 2.87 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.48% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently commented on REGN shares. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Leerink Partners restated a "market perform" rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research note on Thursday, October 24th. Finally, Barclays reduced their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $1,099.55.

View Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

→ Let’s be blunt (From DTI) (Ad)

Should you invest $1,000 in Regeneron Pharmaceuticals right now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines